Mosquito-Borne Diseases: Clinical Trials

368 trials for Mosquito-Borne Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

268 completed, 23 unknown, 20 terminated, 19 recruiting. 368 Phase 2, 85 Phase 1, 43 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2368Completed 268, Unknown 23, Terminated 20, Recruiting 19, Withdrawn 13, Active not recruiting 12, Not yet recruiting 10, Suspended 2, Enrolling by invitation 1
Phase 185Completed 68, Unknown 6, Terminated 3, Not yet recruiting 2, Recruiting 2, Withdrawn 2, Active not recruiting 1, Suspended 1
Phase 343Completed 27, Recruiting 4, Terminated 4, Withdrawn 4, Not yet recruiting 2, Unknown 2

Follow Mosquito-Borne Diseases: new trials by email Literature Review of Mosquito-Borne Diseases trials Research Report on Mosquito-Borne Diseases

Trials (filtered) newest first · largest first

All 368 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
This is a Clinical Study to Assess Whether the Combination of SJ733 and Tafenoquine Will be a Safe and Rapidly Acting Anti-malarial for the Radical Cure of P. Vivax Malaria
SJ733/TQ placebo, CQ/TQ Placebo, CQ/TQ - Malaria, Malaria Vivax
Phase 2Not yet recruitingR. Kiplin Guy1042026-12-012026-10-21
Transmission-Blocking Vaccine Pvs230D1-EPA/Matrix-M in Healthy Malaria-Naive Adults Using a Plasmodium Vivax Controlled Human Malaria Infection and Transmission Model
Plasmodium vivax Challenge Agent Derived from PvHMB-CCE001, Pvs230D1-EPA/Matrix-M - Healthy Volunteers, Malaria
Phase 1 / Phase 2Not yet recruitingNational Institute of Allergy and Infectious Diseases (NIAID)2202026-11-242026-11-19
A Phase 2A Study of a Novel Antimalarial Pyrrolidinamide in Adult Patients With Uncomplicated P. Falciparum Malaria
GSK3772701 600 mg, GSK3772701 900 mg, GSK3772701 150 mg - Malaria, Falciparum
Phase 2RecruitingGlaxoSmithKline702026-10-072026-11-10
Evaluation of IXCHIQ® Vaccine Immunogenicity
IXCHIQ vaccine - Healthy Adult, Healthy Adolescents
Phase 2Not yet recruitingMauro Martins Teixeira752026-09-242026-09-29
Emetine for Viral Outbreaks (a.k.a. EVOLVE Antiviral Initiative)
Emetine Hydrochloride 6mg, Placebo, Emetine Hydrochloride 12mg - Dengue
Phase 2 / Phase 3RecruitingJohns Hopkins University6002026-09-012026-10-13
Tafenoquine Drug Levels in Small Children
Chloroquine, Tafenoquine - Plasmodium Vivax Malaria, Vivax Malaria
Phase 2Not yet recruitingUniversity of Oxford202026-09-012026-09-22
PfSPZ-LARC2 Vaccine in Women of Child-bearing Potential (WOCBP) in Mali
PfSPZ-LARC2 Vaccine, Normal Saline - Malaria (Plasmodium Falciparum)
Phase 2RecruitingSanaria Inc.3002026-07-202026-07-23
Field Trial of PfSPZ-LARC2 Vaccine in Burkinabe Adults
Genetically attenuated PfSPZ Vaccine, Normal Saline (0.9% Sodium Chloride) - Malaria (Plasmodium Falciparum)
Phase 2RecruitingSanaria Inc.1802026-05-042026-06-01
Adaptive Dengue Antiviral Platform Trial
Molnupiravir 400 mg, VIS513 (a monoclonal antibody), Remdesivir 100mg - Dengue, Antiviral Drugs
Phase 2RecruitingOxford University Clinical Research Unit, Vietnam5002026-04-202026-09-28
A Seamless Phase II/III, Observer-blind, to Evaluate Immunogenicity and Safety of Chikungunya Virus Vaccine in Healthy Subjects 12-65Years of Age.
BBV87 Chikungunya vaccine, Placebo - Active Immunisation for Chikungunya Virus Infection
Phase 2 / Phase 3RecruitingBharat Biotech International Limited10002026-04-202026-04-29
A Study of CP-COV03 Compared With Placebo in Participants With Dengue (Part 1) and Dengue-like Illness (Part 2)
CP-COV03, Placebo - Dengue
Phase 2 / Phase 3RecruitingHyundai Bioscience Co., Ltd.2102026-04-092026-07-10
Postpartum 8-aminoquinoline Breast Milk Study
Daily primaquine (0.5 mg/kg per day) for 14 days given with food food and water, Daily primaquine 1 mg/kg per day for 7 days given with food and water, Single-dose tafenoquine given with food and water to prevent gastrointestinal discomfort - Drug Pharmacokinetics in Healthy Volunteers
Phase 2 / Phase 3Not yet recruitingCurtin University602026-04-012026-03-18
Clinical Trial Evaluating Safety and Efficacy of Resomelagon on Dengue Infection (RESOVIR-2)
Resomelagon, Placebo, Standard Treatment - Dengue Fever
Phase 2RecruitingFederal University of Minas Gerais1202026-03-202026-09-15
L9LS-R21 Interaction
Single dose of 1800 mg L9LS SC (12mL), Placebo 12 mL SC, Single dose of 225 mg L9LS SC (1.5mL) - Malaria
Phase 2WithdrawnNational Institute of Allergy and Infectious Diseases (NIAID)2026-03-012026-04-09
Dose Finding Trial of R21/Matrix-M in School Children
5µg R21/50µg Matrix-M, 10µg R21/50µg Matrix-M - Malaria (Plasmodium Falciparum)
Phase 2Active not recruitingUniversity of Oxford402026-02-182026-08-24
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort C2)
KAE609, SoC (Coartem), KLU156 - Uncomplicated Plasmodium Falciparum Malaria
Phase 2RecruitingNovartis Pharmaceuticals1202026-02-122026-10-15
Safety and Efficacy of Imatinib in Combination With Artemether-Lumefantrine for Uncomplicated Malaria
Artemether lumefantrine tablets, Artemether Lumefantrine and Imatinib Mesylate - Malaria (Plasmodium Falciparum)
Phase 2RecruitingVictoria Biomedical Research Institute11162026-01-202026-06-29
Phase IIa/b Trial of PvCS/Montanide ISA-51 Malaria Vaccine in Adults in Chocó, Colombia
PvCS/Montanide ISA-51 VG Vaccine, Placebo - Montanide ISA-51 VG Adjuvant Alone - Plasmodium Vivax Malaria, Plasmodium Vivax Infection
Phase 2Not yet recruitingMalaria Vaccine and Drug Development Center722026-01-192026-01-28
A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M
R21, RH5.1, R78C - Malaria,Falciparum
Phase 2Active not recruitingUniversity of Oxford3602025-12-152026-10-21
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B1)
KAE609 (Cipargamin), SoC (Coartem), INE963 - Uncomplicated Plasmodium Falciparum Malaria
Phase 2CompletedNovartis Pharmaceuticals952025-10-102026-09-10

Showing 20 of 368. Sign in to see all of them.

Narrower conditions

Malaria (177)  ·  Malaria, Falciparum (108)  ·  Dengue (63)  ·  Malaria, Vivax (29)  ·  Severe Dengue (21)  ·  Encephalitis, Japanese (14)  ·  Chikungunya Fever (12)  ·  Yellow Fever (10)  ·  Virus Diseases (9)  ·  Elephantiasis, Filarial (6)  ·  Encephalitis (5)  ·  Malaria, Cerebral (5)  ·  Parasitic Diseases (5)  ·  Rift Valley Fever (5)  ·  West Nile Fever (5)

Broader conditions

Vector Borne Diseases (366)  ·  Infections (364)  ·  Parasitic Diseases (247)  ·  Protozoan Infections (246)  ·  RNA Virus Infections (116)  ·  Arbovirus Infections (114)  ·  Virus Diseases (112)  ·  Flaviviridae Infections (90)  ·  Flavivirus Infections (90)  ·  Hemorrhagic Fevers, Viral (74)  ·  Malaria (70)  ·  Central Nervous System Diseases (32)  ·  Central Nervous System Infections (32)  ·  Nervous System Diseases (32)

Interventions

Artemether, Lumefantrine Drug Combination (22)  ·  Primaquine (22)  ·  Chloroquine (19)  ·  fanasil, pyrimethamine drug combination (16)  ·  Artesunate (15)  ·  Amodiaquine (14)  ·  Saline Solution (14)  ·  Azithromycin (13)  ·  Sodium Chloride (12)  ·  tafenoquine (11)  ·  Rabies Vaccines (9)  ·  Ivermectin (8)  ·  NITD 609 (8)  ·  RTS malaria vaccine (8)  ·  Vaccines (8)

Sponsors

University of Oxford (39)  ·  U.S. Army Medical Research and Development Command (35)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (22)  ·  GlaxoSmithKline (21)  ·  London School of Hygiene and Tropical Medicine (21)  ·  Sanofi Pasteur, a Sanofi Company (19)  ·  Novartis Pharmaceuticals (14)  ·  Medicines for Malaria Venture (13)  ·  Sanofi (11)  ·  Pfizer (7)  ·  Sanaria Inc. (7)  ·  Heidelberg University (6)  ·  Singapore General Hospital (6)  ·  Malaria Vaccine and Drug Development Center (5)  ·  Radboud University Medical Center (5)

Countries

United States (55)  ·  Burkina Faso (35)  ·  Thailand (34)  ·  Mali (31)  ·  Kenya (30)  ·  Gabon (21)  ·  United Kingdom (20)  ·  Brazil (17)  ·  Colombia (17)  ·  Vietnam (17)  ·  Uganda (14)  ·  India (13)  ·  Ghana (12)  ·  Singapore (12)  ·  Mozambique (10)

Top investigators

Kassoum Kayentao, MD, MPH, PhD (5)  ·  Adrian VS Hill, D.Phil, FRCP (4)  ·  James McCarthy, Prof (4)  ·  Adrian V S Hill, MD (3)  ·  Brian Greenwood, FRCP, FRS (3)  ·  Patrick E Duffy, M.D. (3)  ·  Peter Crompton, MD, MPH (3)  ·  Adrian V Hill, DPhill FRCP (2)  ·  Adrian VS Hill, MA, BM BCh, DPhil, DM (2)

Results publications

PMID 39377226, PMID 40099800, PMID 28495354, PMID 42253092, PMID 21443960, PMID 23433102, PMID 23899517, PMID 23962071, PMID 25211344, PMID 26292027, PMID 26292257, PMID 27695088, PMID 28472957, PMID 29324864, PMID 31672143, PMID 32932330, PMID 34179977, PMID 35664997, PMID 36875126, PMID 39308445, PMID 39356094, PMID 41176969, PMID 10190913, PMID 10501745, PMID 11832638, PMID 12011004, PMID 12663340, PMID 15069048, PMID 15714427, PMID 15838784, PMID 16269927, PMID 16338450, PMID 16503464, PMID 16904798, PMID 17213921, PMID 17442466, PMID 17707447, PMID 18231580, PMID 18270560, PMID 18286187, PMID 18320064, PMID 18337339, PMID 18419347, PMID 18545693, PMID 18694333, PMID 18752443, PMID 19098989, PMID 19143532, PMID 19262754, PMID 19365567

NIH funding

2014 (6), 2015 (3), 2018 (2), R01NS074409 (2), 2016 (1), R01HL086488 (1), R01NS102176 (1), U01AI065683 (1), U01AI141981 (1), U01AI195203 (1)